MX336727B - Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida. - Google Patents

Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida.

Info

Publication number
MX336727B
MX336727B MX2013010688A MX2013010688A MX336727B MX 336727 B MX336727 B MX 336727B MX 2013010688 A MX2013010688 A MX 2013010688A MX 2013010688 A MX2013010688 A MX 2013010688A MX 336727 B MX336727 B MX 336727B
Authority
MX
Mexico
Prior art keywords
treatment
aids
peptide derived
receptor coupled
conjugated molecules
Prior art date
Application number
MX2013010688A
Other languages
English (en)
Other versions
MX2013010688A (es
Inventor
Francoise Baleux
Hughes Lortatjacob
David Bonnaffe
Original Assignee
Univ Paris Sud 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Sud 11 filed Critical Univ Paris Sud 11
Publication of MX2013010688A publication Critical patent/MX2013010688A/es
Publication of MX336727B publication Critical patent/MX336727B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención se refiere a una molécula conjugada que comprende un péptido derivado del receptor CD4, dicho péptido está acoplado a una molécula orgánica por medio de un enlazador, en donde: dicho péptido derivado del receptor CD4 comprende la siguiente secuencia general (I) : (I) Xaaf - P1- Lys -Cys - P2 - Cys - P3 - Cys - Xaag- Xaah - Xaai - Xaaj - Cys -Xaak - Cys- Xaal- Xaam, en la cual: P1 representa 3 a 6 residuos de aminoácido, P2 representa 2 a 4 residuos de aminoácidos, P3 representa 6 a 10 residuos de aminoácidos, Xaaf representa N-acetilcisteína (Ac-Cys) o ácido tiopropiónico (TPA) Xaag representa Ala o Gln, Xaah representa Gly o (D)Asp o Ser, Xaai representa Ser o His o Asn, Xaaj representa bifenilalanina (Bip), fenilalanina o [beta]-naftilalanina, Xaak representa Thr o Ala, Xaal representa Gly, val o Leu, y Xaam representa -NH2 o -OH, los residuos de aminoácido en P1, P2 y P3 siendo naturales o no naturales, idénticos o diferentes, dichos residuos de P1 P2 y P3 siendo todos diferentes del residuo Lys y P1, P2 y P3 teniendo una secuencia en común o no, y dicha molécula orgánica comprende un polipéptido aniónico que tiene una secuencia de S-(S-D-X-S)n, en donde n representa un número entero entre 1 y 5, S representa serina y ácido D-aspártico, y X se selecciona a partir del grupo que consiste de: tirosina, sulfotirosina, sulfonato de tirosina, ácido aminosubérico, y p-carboximetil-fenilalanina, y en donde los diversos grupos X son idénticos o diferentes, un grupo molecular A-Z, en donde: A comprende un grupo elegido entre los grupos de la fórmula -CO(CH2)3NH-CO(CH2)2-, - CO(CH2)p-NH-CO-(CH2)q-, -CO(CH2-CH2)- (O-CH2-CH2)p-NH-CO-(CH2)q-, -CO(CH2)p-NH-CO-(CH2)p-NH-CO-(CH2)q-, -CO(CH2)p-NH-CO-(CH2-CH2-O)q -(CH2-CH2)- y -CO(CH2-CH2)-(O-CH2-CH2)p-NH-CO-(CH2-CH2-O)q-(CH2-CH 2)-, en donde p representa un número entero entre 1 y 10 y q representa un número entero entre 1 y 10, y en donde el primero grupo carbonilo está acoplado al extemo N-terminal del polipéptido aniónico, y Z representa un átomo de halógeno, un tiol o un grupo maleimida, dicho polipéptido aniónico está enlazado al enlazador mediante dicho grupo molecular de la fórmula A-Z, el enlazador es el resultado del acoplamiento de un compuesto bifuncional respectivamente con el péptido derivado del receptor CD4 y la molécula orgánica, dicho compuesto bifuncional incorpora dos grupos activos en donde uno de dichos dos grupos activos es capaz de formar un enlace covalente con el grupo amino libre(-NH2) del residuo del aminoácido Lys presente en la secuencia general (I) y el otro grupo activo es un átomo de halógeno o un grupo maleimida cuando Z es un tiol o un grupo tiol protector cuando Z es un átomo de halógeno o un grupo maleimida.
MX2013010688A 2011-03-18 2012-03-16 Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida. MX336727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305309A EP2505210A1 (en) 2011-03-18 2011-03-18 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids
US201261590992P 2012-01-26 2012-01-26
PCT/EP2012/054674 WO2012126833A1 (en) 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids

Publications (2)

Publication Number Publication Date
MX2013010688A MX2013010688A (es) 2014-03-27
MX336727B true MX336727B (es) 2016-01-27

Family

ID=44118425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010688A MX336727B (es) 2011-03-18 2012-03-16 Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida.

Country Status (9)

Country Link
US (1) US9078928B2 (es)
EP (2) EP2505210A1 (es)
JP (1) JP6046060B2 (es)
CN (1) CN103429269B (es)
BR (1) BR112013023859A2 (es)
CA (1) CA2830012C (es)
MX (1) MX336727B (es)
WO (1) WO2012126833A1 (es)
ZA (1) ZA201306956B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062854A1 (en) * 2014-10-24 2016-04-28 Institut Pasteur Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
US10527600B2 (en) 2016-04-18 2020-01-07 Icagen, Inc. Sensors and sensor arrays for detection of analytes
WO2018140590A1 (en) * 2017-01-25 2018-08-02 Massachusetts Institute Of Technology Seft-labeling miniproteins and conjugates comprising them
CN109081789B (zh) * 2017-06-13 2021-01-01 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰脂肪氨基酸，其合成，活性和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338600A (ja) * 2001-05-17 2002-11-27 Japan Science & Technology Corp Ｈｉｖ−１の感染を抑制するポリペプチド
RU2270690C1 (ru) * 2004-06-11 2006-02-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Комплексное анти-вич соединение
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
EP2087911A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS

Also Published As

Publication number Publication date
EP2505210A1 (en) 2012-10-03
MX2013010688A (es) 2014-03-27
US9078928B2 (en) 2015-07-14
JP2014509604A (ja) 2014-04-21
CA2830012A1 (en) 2012-09-27
US20140107043A1 (en) 2014-04-17
EP2686019B1 (en) 2017-03-01
ZA201306956B (en) 2014-05-28
CA2830012C (en) 2018-11-06
WO2012126833A1 (en) 2012-09-27
EP2686019A1 (en) 2014-01-22
CN103429269A (zh) 2013-12-04
CN103429269B (zh) 2016-05-11
JP6046060B2 (ja) 2016-12-14
BR112013023859A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CL2013003406A1 (es) Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ626302A (en) Bispecific binding molecules for anti-angiogenesis therapy
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
WO2009087082A3 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
MX2013007559A (es) Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido.
MX2011008621A (es) Proceso para la purificacion de lipopeptidos.
UA115542C2 (uk) Процес синтезу терапевтичних пептидів
NZ723229A (en) Immunogens for hiv vaccination
WO2014057436A3 (en) Anticancer conjugate
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX336727B (es) Moleculas conjugadas nuevas que comprendenun peptido derivado del receptor cd4 acoplado a un polipeptido polianionico para el tratamiento de sida.
HK1163659A1 (en) Process for the preparation of ajoene
GB201210256D0 (en) Improved butanol recovery process
IN2014DN09367A (es)
IN2015DN03203A (es)
WO2009098147A3 (en) Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanion for the treatment of aids
PH12015501952B1 (en) Improved preparation method for high-yield production of physiologically active polypeptide conjugate
SG195302A1 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
MY171770A (en) An apparatus for continuous separation of valine and a method for continuous separation of valine using the same
IN2012MU03517A (es)